Biontech announces first quarter 2025 financial results and corporate update

Continued oncology pipeline advancement with a strategic focus on two priority pan-tumor programs: next-generation immunomodulator bnt327, a bispecific antibody targeting pd-l1 and vegf-a 1 , and mrna cancer immunotherapies presented multiple clinical updates across oncology pipeline underlining biontech's combination strategy in oncology with first data presented for the novel combination of bnt327 plus antibody-drug conjugates (“adcs”) development and commercial preparation for a 2025/2026 season variant-adapted covid-19 vaccine first quarter 2025 revenues of €0.2 billion 2 , net loss of €0.4 billion and basic and diluted loss per share of €1.73 ($1.823) maintained strong financial position with €15.9 billion in cash, cash equivalents and security investments as of march 31, 20254 full year 2025 financial guidance confirmed conference call and webcast scheduled for may 5, 2025, at 8:00 a.m. edt (2:00 p.m.
BNTX Ratings Summary
BNTX Quant Ranking